Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7351 to 7400 of 8236 results

  1. Osteoarthritis - diacerein [ID332]

    Discontinued Reference number: GID-TAG250

    Technology appraisal guidance
    Discontinued

  2. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued Reference number: GID-TAG278

    Technology appraisal guidance
    Discontinued

  3. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued Reference number: GID-TAG418

    Technology appraisal guidance
    Discontinued

  4. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

    Technology appraisal guidance
    Discontinued

  5. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued Reference number: GID-TAG420

    Technology appraisal guidance
    Discontinued

  6. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

    Technology appraisal guidance
    Discontinued

  7. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  8. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued Reference number: GID-TAG423

    Technology appraisal guidance
    Discontinued

  9. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

    Technology appraisal guidance
    Discontinued

  10. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued

  11. Osteoarthritis - naproxcinod [ID417]

    Discontinued Reference number: GID-TAG426

    Technology appraisal guidance
    Discontinued

  12. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued Reference number: GID-TAG427

    Technology appraisal guidance
    Discontinued

  13. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued Reference number: GID-TAG431

    Technology appraisal guidance
    Discontinued

  14. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

    Technology appraisal guidance
    Discontinued

  15. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  16. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  17. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued Reference number: GID-TAG436

    Technology appraisal guidance
    Discontinued

  18. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  19. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued Reference number: GID-TAG439

    Technology appraisal guidance
    Discontinued

  20. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  21. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued Reference number: GID-TAG444

    Technology appraisal guidance
    Discontinued

  22. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued Reference number: GID-TA10316

    Technology appraisal guidance
    Discontinued

  23. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    In development Reference number: GID-TA11486 Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued Reference number: GID-TA10929

    Technology appraisal guidance
    Discontinued

  25. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued

  26. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued

  27. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  28. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  29. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  30. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  31. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  32. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued

  33. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued Reference number: GID-TAG496

    Technology appraisal guidance
    Discontinued

  34. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    In development Reference number: GID-TA11442 Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    In development Reference number: GID-TA11466 Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development Reference number: GID-TA10607 Expected publication date: TBC

    Technology appraisal guidance
    In development

  38. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued Reference number: GID-TA11024

    Technology appraisal guidance
    Discontinued

  39. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312

    In development Reference number: GID-TA11329 Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Technology appraisal guidance
    Published
    26 June 2001

  41. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Evidence summary
    Published
    2 November 2012

  42. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    16 June 2015

  43. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Technology appraisal guidance
    Published
    12 July 2023

  44. Smoking: harm reduction (QS92)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Quality standard
    Published
    2 July 2015

  45. Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Quality standard
    Published
    23 July 2015

  46. Obesity in adults: prevention and lifestyle weight management programmes (QS111)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Quality standard
    Published
    19 January 2016

  47. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

    Quality standard
    Last updated
    18 August 2016

  48. Dementia: support in health and social care (QS1)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Quality standard
    Published
    29 June 2010

  49. Obesity: clinical assessment and management (QS127)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Quality standard
    Published
    4 August 2016

  50. Epilepsy in adults (QS26)

    This quality standard has been updated and replaced by NICE quality standard 211. 

    Quality standard
    Published
    28 February 2013